论文部分内容阅读
目的：观察新型非类固醇类抗炎药—舒林酸对实验性高钙尿症的防治作用，探讨其可能机制。 方法：建立大鼠实验性高钙尿症模型，观察舒林酸治疗后２ 周和４ 周尿 Ｃａ 、尿 Ｃａ／ Ｃｒ 、尿 Ｎ Ａ Ｇ／ Ｃｒ 以及肾和十二指肠 Ｃａ２ ＋ Ａ Ｔ Ｐ 酶（ 钙泵） 的变化。 结果：２ 周和４ 周时尿 Ｃａ 、尿 Ｃａ／ Ｃｒ 、尿 Ｎ Ａ Ｇ／ Ｃｒ 及肾和十二指肠 Ｃａ２ ＋ Ａ Ｔ Ｐ 酶均显著下降（ Ｐ＜ ００１） ，２４ｈ 尿钙定量与尿 Ｎ Ａ Ｇ／ Ｃｒ 值呈正相关（ Ｐ＜ ００１） 。 结论：舒林酸对高钙尿症具降尿钙和保肾作用，其机制可能与下调维生素 Ｄ 靶组织钙泵活性有关。
Objective: To observe the preventive and therapeutic effects of sulindac, a new non-steroidal anti-inflammatory drug, on experimental hypercalciuria and to explore its possible mechanism. Methods: The model of experimental hypercalciuria in rats was established. Urinary Ca, urinary Ca / Cr, urine N A G / Cr and renal and duodenal Ca2 + A T P were observed at 2 and 4 weeks after sulindac treatment Changes in enzyme (calcium pump). Results: Urine Ca, urinary Ca / Cr, urine N A G / Cr and renal and duodenal Ca2 + A T Pases were significantly decreased at 2 weeks and 4 weeks (P <001) And urine N A G / Cr values were positively correlated (P <0 01). CONCLUSIONS: Sulindac has the effect of lowering urinary calcium and protecting kidney in hypercalciuria, which may be related to the down-regulation of calcium pump activity in target tissues of vitamin D.